IP Library Granted Patent US 8,785,184
Granted Patent B2
US 8,785,184 · App. 12/839,041 · Granted Jul 22, 2014

Differentiation of human embryonic stem cells

Inventor: Jean Xu (Skillman, NJ)
Assignee: Janssen Biotech, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,785,184
App. No.
12/839,041
Granted
Jul 22, 2014
Kind
B2
Abstract

The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells capable of producing insulin following transplantation into an animal.

Claims (6)

1. A method to differentiate a population of human pluripotent stem cells into a purified population of pancreatic endoderm cells that co-express PDX-1 and NKX-6.1, but do not express CDX-2 and NGN-3 comprising the steps of:

(a) culturing human pluripotent stem cells,

(b) differentiating the human pluripotent stem cells into definitive endoderm cells by treating the human pluripotent stem cells with a medium supplemented with a TGF-β receptor agonist,

(c) differentiating the definitive endoderm cells into a population of pancreatic endoderm cells that co-express PDX-1 and NKX6.1, but do not express CDX2 and NGN3 by treating the definitive endoderm cells with a first medium supplemented with FGF7, followed by culturing the cells in a second medium supplemented with FGF7, a factor capable of inhibiting BMP, retinoic acid, and a hedgehog signaling pathway inhibitor, and a TGF-β receptor agonist selected from the group consisting of: activin B, TGFβ-I, TGFβ-II, GDF-8, and GDF-11, and

(d) selecting cells which co-express PDX-1 and NKX6.1 and do not express CDX2 and NGN3 to obtain a purified population of pancreatic endoderm cells that co-express PDX-1 and NKX-6.1, but do not express CDX-2 and NGN-3.

2. The method of claim 1 , wherein the hedgehog signaling pathway inhibitor is cyclopamine-KAAD.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2014
From: XU, JEAN
To: CENTOCOR ORTHO BIOTECH, INC.
Reel/Frame 033126/0903 →
CHANGE OF NAME Recorded Jun 18, 2014
From: CENTOCOR ORTHO BIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 033193/0358 →
Continuity (2)
Provisional Application 61226936 · Jul 20, 2009
Related Publication 20110014702A1 · Jan 20, 2011